Get In Touch
Tmapril cpver 104x80.jpg
Current Issue

animation-neutral-tts-300x100' width='300' height='100' border='0

Grasim Industries consolidated PAT at Rs.4,425 crore

By Niranjan Mudholkar,

Added 15 June 2020

Consolidated revenue for the FY20 stood at Rs.77,625 crore

On standalone basis the company continues to maintain a comfortable liquidity position with Liquid investments of Rs.2,093 Cr. as at 31st March, 2020.

Grasim Industries Limited has announced its audited financial results for the quarter and year ended 31st March, 2020.

Consolidated Revenue and EBITDA for the FY20 stood at Rs.77,625 Cr. and Rs.13,846 Cr. respectively. Consolidated PAT at Rs.4,425 Cr. recorded a growth of 161% YoY aided by write back of deferred tax liabilities and lower exceptional charge in the current year.

Consolidated Revenue and EBITDA for the Q4FY20 stood at Rs.19,902 Cr. and Rs.3,243 Cr. respectively. Consolidated PAT for the Q4FY20 at Rs.1,506 Cr. recorded a growth of 32% YoY.

On a standalone basis, Revenue and EBITDA for FY20 declined on account of general economic slowdown and start of the lock down in major economies of the world during the month of March 2020.

Despite the economic slowdown, the company generated net cash flow from operations of Rs.3,519 Cr. on standalone basis in FY20 (before meeting its capex spend of over Rs.2,800 Cr.) on the back of efficient operations and working capital management during the year. On standalone basis the company continues to maintain a comfortable liquidity position with Liquid investments of Rs.2,093 Cr. as at 31st March, 2020.

 

COVID-19 Impact

Consequent to the national lockdown across country, all operations of the Company were suspended except at the fertilizer plant in Jagdishpur(U.P). Operations have since partially resumed across all businesses of the company. All Grasim plants are currently operating in the range of ~25 to over 100% capacity utilization. The Company has implemented comprehensive measures and SOPs across its plants to ensure safety against COVID-19 infection post resumption.
END

comments powered by Disqus